$1.40
+0.14 (+11.11%)
Open$1.27
Previous Close$1.26
Day High$1.45
Day Low$1.26
52W High$1.45
52W Low$0.70
Volume—
Avg Volume482.9K
Market Cap56.77M
P/E Ratio—
EPS$-0.33
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+2,575.0% upside
Current
$1.40
$1.40
Target
$37.45
$37.45
$24.30
$37.45 avg
$44.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.29M | 3.79M | 3.81M |
| Net Income | -12,817,044 | 783.4K | 928.9K |
| Profit Margin | -994.5% | 20.7% | 24.4% |
| EBITDA | -14,353,792 | 1.80M | 1.92M |
| Free Cash Flow | — | 820.9K | 949.0K |
| Rev Growth | — | +6.9% | +13.5% |
| Debt/Equity | — | 0.92 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |